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Role of Sirtuins in Adipose Tissue
Development and Metabolism
Alina Kurylowicz
Abstract
Sirtuins (silent information regulators, sirts) via modification of histones, as well
as transcription factors and co-regulators, control expression of other
genes, particularly those involved in the organism response to stress. Detection
of sirtuin expression in adipocytes initiated interest in their role in adipose tissue
development and metabolism. This chapter presents how sirtuins control the
critical steps of preadipocytes’ differentiation and proliferation, as well as the
process of adipose tissue browning. Moreover, it shows in vitro and in vivo
data proving that sirtuins are involved in the regulation of lipogenesis,
lipolysis, and secretory activity of adipose tissue. Due to all these reasons,
sirtuins may constitute potential targets in the treatment of obesity and
related complications.
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1. Introduction
Recent research widened our understanding of the role of adipose tissue
from the simple energy storage to the metabolically and hormonally active organ
that in response to environmental stimuli is able not only to activate lipolysis/
lipogenesis but also to secrete several factors to communicate with and regulate
the function of other organs. These findings allowed to understand the link
between excess adiposity and the development of obesity-related complications
and renewed interest in adipose tissue as a possible target for obesity-orientated
therapies [1].
However, despite the constant progress in understanding its pathogenesis, the
therapeutic potential to prevent and combat obesity is limited. Behavioral inter-
ventions, calorie restriction (CR) combined with the increased physical activity, do
not assure persistent, long-term effects, while available pharmacological treatments
allow for loss of 5–10% of initial weight. Therefore, there is a need for novel
methods of treatment of obesity and its complications.
Studies on the influence of CR on the whole body function allow to identify
sirtuins (silent information regulators, sirts)—essential players in different cellular
metabolic pathways that seem to be crucial for the proper function of adipose tissue
and in this way may constitute attractive therapeutic targets in the treatment of
obesity and related complications.
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2. A short review of the sirt system
The sirts are highly conserved regulatory proteins present almost in all species.
Initially, they have been identified as class III histone deacetylases, nicotinamide
adenine dinucleotide (NAD)-dependent enzymes responsible for the removal of
acetyl groups from lysine residues in proteins, while some members of this family
act also as mono-ADP-ribosyltransferases. Since acetylation and deacetylation are
essential mechanisms of posttranslational modifications of proteins determining
their activity, sirts were found to be involved in the regulation of distinct cellular
pathways including, among others, those related to cell survival, apoptosis, inflam-
matory and stress responses, as well as lipid and glucose homeostases [2].
In human, seven sirt genes (sirts) have been identified that encode seven
sirt enzymes of different structure, cellular localization, and tissue expression. All of
them share a common conserved catalytic core region consisting of approximately 275
amino acids, forming a Rossmann fold domain (characteristic of NAD+/NADH-binding
proteins) and a zinc-binding domain connected by several loops [2]. Outside the
catalytic core, sirt enzymes possess variable N- and C-terminal regions that decide
about their enzymatic activities, binding partners and substrates, as well as subcellular
localization [3]. sirt1, sirt6, and sirt7 localize predominantly in the nucleus where via
modifications of transcription factors, cofactors, and histones they participate in the
regulation of energy metabolism, stress and inflammatory responses, DNA repair (sirt1
and sirt6), and rDNA transcription (sirt7) [4]. sirt2 is a cytoplasmic sirtuin and plays a
role in cell cycle control [5]. sirt3 can be found in mitochondria where it takes part in
the regulation of enzymes involved, e.g., in glycolysis, fatty acid (FA) oxidation, ketone
body synthesis, and the catabolism of amino acids as well as of apoptosis and oxidative
stress pathways. This sirtuin also has as a nuclear full-length form (FL-sirt3) that is
processed to the short mitochondrial form. Therefore, sirt3 may regulate cellular
metabolism both at the transcriptional and posttranscriptional levels. sirt4 is also local-
ized in mitochondria and acts as ADP-ribosylase. Another mitochondrial sirtuin—sirt5
—has a potent demalonylation and desuccinylation enzymatic activity and is involved
in the regulation of amino acid catabolism [6]. Importantly, the subcellular localization
of sirts may vary in different cell types and may depend on their molecular interactions
as it was shown in the case of sirt1, sirt2, and sirt3 that can be found both in the nucleus
and in the cytoplasm [4].
Expression of sirtswas detected in various human tissues, including those crucial for
the regulation of metabolism, e.g., hypothalamus, liver, pancreatic islets, skeletal mus-
cles, and adipocytes [7–10]. In these tissues, sirts control the expression of other genes,
particularly those involved in the organism response to stress. It was shown that sirt
expression and activity of sirt enzymes are highly sensitive to several environmental
factors, CR, exercise, and cold exposure that represents an adaptive mechanism in
response to environmental stress [3]. Fluctuations in intracellular NAD+ levels in
response to nutrient availability are believed to mediate in this phenomenon. When
nutrients are plentiful, cellular metabolism relies on glycolysis to produce energy,
leading to the generation of ATP and conversion of NAD+ to NADH. Low levels of
NAD+ and high levels of NADH result in inactivation of the enzymatic activity of sirts.
In turn CR leads to the elevation of NAD+ levels in most metabolically active tissues
resulting in the increased sirt activity [11]. In humans, obesity leads to downregulation
of sirt1 level in adipose tissue that can be restored by the weight loss [12].
3. sirts and adipogenesis
sirts are considered as potential targets for the treatment of obesity that results
from their involvement in the regulation of adipogenesis and adipocyte browning.
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3.1 Types of adipocytes
In mammals, there are two main types of adipose tissue that differ in their
structure, physiology, and function. White adipose tissue (WAT) acts mainly as
energy storage that releases FA for the production of adenosine triphosphate (ATP)
during the process of β-oxidation.
Small mammals and human newborns, apart from white adipocytes, possess
large deposits of brown adipose tissue (BAT) responsible for the non-shivering
(adaptive) thermogenesis which is for them the most important regulatory mecha-
nism for maintaining body temperature. The energy produced due to the oxidation
of lipolysis-derived FA in the BAT mitochondria is released as heat, mostly thanks
to uncoupling proteins (UCP). Age progression in humans was believed to be
associated with complete atrophy of BAT; however, novel methods of imaging led
to the identification of BAT stores in several areas of the adult human body, as
well as of cells reminding brown adipocytes dispersed within WAT also known as
beige/brite adipocytes (BeAT). These cells share common morphological features of
white and brown adipocytes, and their number may increase upon different stimuli
(e.g., cold, exercise, thyroid hormones, resveratrol). There are two theories regard-
ing BeAT origin: they (i) differentiate from the progenitor cells resident in WAT or
(ii) arise due to the transdifferentiation of white adipocytes. Given the role of
adaptive thermogenesis in the whole body energy expenditure, stimulation of white
adipocytes browning seems to be an attractive therapeutic pathway in the treatment
of obesity and related metabolic disorders [13].
3.2 sirts and preadipocyte differentiation
Peroxisome proliferator-activated receptor γ (PPARγ) is considered to be the
main transcription factor responsible for promoting adipogenesis. sirt1, by
interacting with two PPARγ corepressors, nuclear receptor corepressor (N-CoR)
and silencing mediator of retinoid and thyroid hormone receptors (SMRT), can
attenuate adipogenesis [14]. Consistently, overexpression of ectopic sirt1 blocks
adipogenesis in 3T3-L1 cells, a culture of mouse adipocytes used as a model of
adipocyte differentiation [15, 16]. Additionally, via activation of the Wnt signaling
pathway, sirt1 determinates mesenchymal stem cells (MSC) differentiation toward
myogenic cells, while its inhibition in MSC promotes adipogenesis [17]. MicroRNA
146b (miR-146b) acts as a negative regulator of sirt1 during adipocyte differentia-
tion, giving a hope that interference with this miRNA may constitute a therapeutic
perspective in the treatment of excess adiposity [18].
Another sirtuin family member—sirt2—has also shown an inhibitory effect on
adipocyte differentiation [14]. In this process, sirt2 deacetylates forkhead box O1
(FOXO1) transcription factor and subsequently represses PPARγ transcriptional
activity [19]. Therefore, sirt2 overexpression inhibits adipogenesis, while its silenc-
ing has an opposite effect in 3 T3-L1 preadipocytes. Moreover, this inhibitory
influence of sirt2 on adipocyte differentiation discloses under CR that indicates the
role of this sirtuin in the maintenance of energy homeostasis and suggests that sirt2
activators could provide novel therapeutics of obesity and its complications; how-
ever, such compounds have not been developed yet.
sirt3 is essential for the activation of bioenergetic function of mitochondria at
the early stage of adipocyte differentiation. Silencing of sirt3 decreases the protein
level of forkhead box O3a (FoxO3a) transcription factor and subsequently
downregulates the expression of several antioxidant enzymes and increases oxida-
tive stress in MSCs after adipogenic induction. In this way, sirt3 depletion dimin-
ishes the ability of MSCs to undergo adipogenic differentiation and leads to
adipocyte dysfunction [20].
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Knockout of sirt4 (encoding sirt4) leads to the decreased expression of
adipogenic differentiation marker genes during differentiation of bovine adipo-
cytes, suggesting that this sirtuin is crucial for the proper adipogenesis too [21].
sirt6 and sirt7 were also found to be necessary for adipocyte differentiation, and
their deficiency inhibits the development of preadipocytes toward white
adipocytes. sirt6 inhibits the expression of kinesin family member 5C (KIF5C)
and enhances casein kinase 2 (CK2) and in this way promotes mitotic clonal
expansion of adipocytes [22]. Deletion of sirt7 or inhibition of sirt7 diminishes the
ability of mouse embryo fibroblasts and 3T3L1 cells to undergo adipogenesis.
However, its overexpression did not rescue the preadipocyte differentiation,
suggesting that sirt7 is required but not sufficient to perform a full program of
adipogenesis. Interestingly, sirt7 is a metabolic target for miR-93, a negative
regulator of adipogenesis, which expression is decreased in genetically obese
ob/ob mice [23].
Experimental data suggest a direct interaction between sirt1 and sirt7 proteins at
the molecular level as it was shown in immunoprecipitation assays and in vivo,
where sirt7 knockout (KO) mice have increased sirt1 protein levels and enzymatic
activity in WAT. Loss of sirt7 leads to increased sirt1 activity and recruitment to the
PPARγ promoter, causing downregulation of its expression, that can explain the
lipodystrophic phenotype in sirt7 KO mice [24].
The role of sirts in preadipocyte differentiation is schematically shown in
Figure 1.
3.3 sirts and adipocyte browning
One of the approaches to the treatment of obesity is based on the activation in
preadipocyte genes specific to BAT, which is characterized by high metabolic
activity. Browning (brightening or beiging) of white adipocytes is an adaptive and
reversible process that occurs in response to various stimuli.
Since sirt1, by direct deacetylation of PPARγ, recruits the BAT program
coactivator Prdm16 (PR domain containing 16) to PPARγ, it also plays a crucial role
Figure 1.
Role of sirtuins in adipocyte differentiation. CK2, casein kinase 2; FOXO1, forkhead box O1; FOXO3a,
forkhead box O3a; KI5FC, kinesin family member 5C; PPARγ, peroxisome proliferator-activated receptor γ;
ROS, reactive oxygen species; sirt, sirtuin; Wnt, signaling pathway;↑, upregulation and stimulation;↓,
downregulation and inhibition.
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in the induction of genes typical for BAT and repression of WAT genes associated
with insulin resistance [25]. Therefore, silencing of sirt1 in 3T3-L1 preadipocytes
leads to their hyperplasia and increased expression of WAT and inflammatory
markers with a parallel decrease in BAT markers, whereas its activation results in
increased adipocyte browning [26].
Cooperation among different sirtuins is crucial for the proper differentiation of
brown adipocytes. For example, nutritional and thermal stress induces sirt1, which,
by its deacetylation, activates PPARγ coactivator 1α (PGC-1α) which upregulates
transcription of sirt3. In cultures of brown adipocyte precursors (HIB1B cells),
overexpression of sirt3 resulted in the increased phosphorylation of the cAMP
response element-binding protein (CREB) which then directly activates PGC-1α pro-
moter, resulting in the increased expression of UCP1 and in promotion of mito-
chondrial respiration [27]. However, subsequent experiments showed that the
protein produced based on the cDNA used in this experiment lacked proper
deacetylase activity, so this finding should be treated with caution [28]. Moreover,
sirt3 KO mice, despite mitochondrial protein hyperacetylation, showed no
significant disturbances of the adaptive thermogenesis [29].
sirt5 was found to be essential for activation of brown adipogenic genes,
and adipocyte differentiation in vitro and its knockout leads to the decrease in
intracellular α-ketoglutarate concentration, which results in elevated histone
methylation and transcriptional repression of pparγ and Prdm16. Therefore sirt5 KO
mice present diminished browning capacity of WAT with subsequent cold intoler-
ance [30].
Finally, depletion of sirt6 in primary brown adipocytes reduces binding of the
activating transcription factor 2 (ATF2) to the PGC-1α promoter and in this way
decreases basal mitochondrial respiration and maximal mitochondrial capacity [31].
The role of sirts in adipocyte browning is schematically shown in Figure 2.
4. sirts in control of adipose tissue function
Both in vitro and in vivo studies have implicated sirts in the regulation of
adipose tissue metabolism. These studies let us understand the complexity of sirt
Figure 2.
Role of sirtuins in adipocyte browning. PGC-1α, PPARγ coactivator 1α; PPARγ, peroxisome proliferator-
activated receptor γ; Prdm16, PR domain containing 16; sirt, sirtuin; UCP, uncoupling protein 1;↑,
upregulation and stimulation.
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actions and gave hope that the modulation of their activity may constitute a new
therapeutic strategy for the treatment of obesity and its metabolic complications
including hyperlipidemia and chronic inflammation.
4.1 sirts in lipid metabolism
sirts are expressed in tissues and organs involved in lipid metabolism including
the liver, skeletal muscle, and white and brown adipose tissues, where they control
lipid synthesis, storage, and utilization both directly and indirectly (via control of
insulin secretion).
During fasting sirt1, by deacetylation of PPARγ corepressors (FOXO1 and PGC-
1α), stimulates in the adipose tissue transcription of the gene encoding adipose
triglyceride lipase (ATGL) and subsequent lipolysis. This process is impaired in sirt1
KO mice [15]. However, the results of animal studies regarding sirt1 overexpression
on body weight and composition are inconsistent [32, 33]. It is suggested that these
discrepancies may be attributed to the different levels of sirt1 expression between
the transgenic animals as well as to the differences between strains and species used
in the experiments.
Apart from the regulation of PPARα-related pathways, sirt1 may influence FA
metabolism via downregulation of sterol regulatory element-binding proteins 1 and
2 (SREBP-1 and SREBP-2) transcription factors. sirt1 overexpression or its activa-
tion by, e.g., resveratrol (RSV), prevents cleavage-induced activation of SERBs and
their translocation to the nucleus where they promote transcription of genes crucial
for sterol biosynthesis [34]. sirt1 KO mice have lower SREBP-1 mRNA levels in the
liver that correlates with decreased serum triglyceride concentrations [35]. Activa-
tion of sirt1 also induces phosphorylation of AMP-activated protein kinase (AMPK)
that protects against FA synthase induction and lipid accumulation caused by high
glucose [36].
sirt1 also promotes deacetylation of liver X receptor (LXR) proteins and tran-
scription factors that act as cholesterol sensors and regulate whole body cholesterol
and lipid homeostasis [37]. LXR deacetylation is necessary both for their activation
and induction of LXR target genes and for their subsequent ubiquitination. sirt1 KO
animals have reduced mRNA levels of LXR target genes that result in impaired
reverse cholesterol transport—a process by which excess cholesterol is removed
from the peripheral cells and transported to the liver where it can be converted to
bile and excreted [38].
Fasting and cold exposure were found to increase the expression of sirt2 in
WAT. That results in the deacetylation of FOXO1 and subsequent repression of
PPARγ activity, lipolysis, and release of FA. Similar effect can be obtained by
administration of isoproterenol that confirms the role of adrenergic signaling in the
regulation of sirt2 expression in WAT [19]. sirt2 may also inhibit lipogenesis by
deacetylation of ATP-citrate lyase (ACLY), an enzyme crucial for FA synthesis. A
deacetylated form of ACLY is then ubiquitinated and degraded, while lipogenesis is
reduced [39].
Livers from sirt3 KO mice showed higher levels of FA oxidation intermediate
products and triglycerides during fasting that was associated with decreased levels
of FA oxidation when compared to wild-type animals. These findings are consistent
with the fact that deacetylation of the long-chain acyl-coenzyme A dehydrogenase
by sirt3 was found to determine proper mitochondrial FA oxidation [40].
There are experimental data that other sirts are also involved in lipid metabo-
lism: in adipose tissue, e.g., deacetylation of malonyl-CoA-decarboxylase by sirt4
and desuccinylation of the hydroxyl-coenzyme A dehydrogenase by sirt5 determine
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proper mitochondrial FA oxidation [41, 42], while downregulation of sirt4 level
results in the increased expression of genes involved in FA oxidation [43]. In
experimental animals, sirt6 deficiency leads to impaired lipolytic activity and sub-
sequent adipocyte hypertrophy [44]. On the molecular level, sirt6 deficiency
increases the acetylation and phosphorylation of FOXO1, leading to its nuclear
exclusion and decrease in its transcriptional activity that downregulates the expres-
sion of the gene encoding ATGL [44]. In turn, sirt6 overexpression in adipose tissue
counteracts lipotoxicity caused by the high-fat diet by decreasing PPARγ signaling
and diacylglycerol acyltransferase 1 (DGAT1) activity [45]. The role of sirt7 in lipid
metabolism is yet to be determined. In some studies sirt7 KO mice, due to the
impaired management of the endoplasmic reticulum stress, have increased lipo-
genesis in the liver that results in liver steatosis and dyslipidemia [23], while sirt7
upregulation restores hepatic homeostasis in diet-induced obesity [46]. On the
contrary, other researchers showed that sirt7 via inhibition of testicular receptor 4
(TR4) degradation promotes FA uptake, triglyceride biosynthesis, and storage [47].
These results constituted the basis for studies on the use of sirtuin-activating
compounds in order to increase lipolysis and to prevent excess adiposity.
4.2 sirts in control of adipose tissue inflammation and secretory activity
Recent years widened our understanding of the role of WAT which is now
considered not only an energy storage but also an important endocrine organ that
via secreted mediators (e.g., cytokines and adipokines) may influence the function
of the whole organism and be responsible for the development of obesity-related
complications.
sirt1, by interference with the nuclear factor κB (NF-κB) signaling pathway,
represses inflammatory gene expression in adipocytes and in macrophages infil-
trating adipose tissue, which results in the improvement of insulin signaling and in
the reduction of hyperinsulinemia accompanied by an increase in insulin sensitivity
in vivo [48, 49]. sirt1 can inhibit NF-κB signaling both directly and indirectly.
Acting directly sirt1 deacetylates the RelA/p65 subunit of the NF-κB, leading to its
subsequent ubiquitination and degradation. Indirect inhibition of NF-κB by sirt1
takes place by increasing activity of repressive transcriptional complexes, e.g.,
PPARα, which can bind and inactivate RelA/p65 or increase expression of the gene
encoding inhibitor α of κB (IκBα) [50].
Similarly, overexpression of sirt6 suppresses activation of the NF-κB signaling in
cell lines, firstly, by the direct interaction with NF-κB subunit and, secondly, by
deacetylation of histone H3 lysine 9 at target gene promoters leading to inhibition of
the transcription of the proinflammatory genes [51]. Moreover, sirt6 by binding to
the c-Jun downregulates expression of its target genes including interleukin 6
(IL-6), tumor necrosis factor α (TNF-α), and monocyte chemoattractant protein 1
(MCP-1) [52]. Subsequently, in model animals, sirt1 and sirt6 deficiency increases
macrophage infiltration in adipose tissue and subsequent inflammation [44].
Moreover, sirt1 deficiency in adipocytes (probably due to the decreased expression
of IL-4) led to the shift between the profiles of macrophages from the anti-
inflammatory (M2) to the proinflammatory (M1) [53]. Therefore, sirt1- and sirt6-
deficient adipocytes are more potent in promoting macrophages migration than
wild-type cells that can be reversed by addition of MCP1 or adiponectin.
This last adipokine is a protein hormone with many desirable metabolic proper-
ties (including anti-inflammatory and anti-oxidative effects) almost exclusively
produced in adipocytes. sirt1 tightly regulates the expression and secretion of
adiponectin by adipocytes: enhancing formation of the complex between FOXO1
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and C/EBPα (CCAAT/enhancer binding protein α) increases expression of the
ADIPOQ gene, while inhibition of endoplasmic reticulum oxidoreductase Ero-Lα
decreases secretion of the high-molecular-weight (HMW) adiponectin [54].
Omentin-1 (intelectin-1) is another adipokine secreted, but not only by adipose
tissue with anti-inflammatory properties that via activation of sirt1 exert its molec-
ular effects on target genes [55].
In contrary, resistin is a hormone with biological characteristics opposite to
adiponectin and omentin. It is secreted, apart from other sites, by adipose tissue;
however, resistin expression in isolated human adipocytes is low, and its content in
adipose tissue is proportional to the intensity of macrophages infiltration, which are
the primary source of this adipokine [56]. Stimulation of sirt1 by RSV reduces
resistin mRNA level and protein expression in macrophages, whereas sirt1 KO
results in the opposite effect. On the molecular level, sirt1 interacts directly with the
resistin promoter region at an activator protein 1 (AP-1) transcription factor
response element as well as inhibits transactivation of the resistin gene by c-Jun
pathway [57]. In animal model RSV, via activation of sirt1 was also found to
decrease expression of visfatin—another adipokine secreted by macrophages
infiltrating adipose tissue [58].
5. Sirtuins as targets for obesity treatment
Given their role in the regulation of lipid metabolism, adipogenesis and secre-
tory activity of adipose tissue sirts constitute promising targets for novel therapies,
targeting excess adiposity and associated metabolic disorders. However, the dis-
covery of a compound that would be able to activate some sirt isoforms and to
inhibit others is still a challenge. Another obstacle is to obtain tissue specificity of
action for these compounds, since sirt activity may depend on the cell type and
environmental factors.
Several sirt isoforms bear the potential for being used as therapeutic targets,
but to date, only modulators of sirt1 have entered into the clinic. The most
effective sirtuin-activating compound able to increase sirt1 activity in vitro by >10
fold is RSV [59]. RSV, naturally present in grapes and red wine, successfully
inhibited maturation of preadipocytes and induced adipocyte apoptosis in cell
cultures [60]. When administered to mice on the high-calorie diet, RSV was able
to improve their metabolic and inflammatory profiles [61]. A reformulated ver-
sion of RSV (resVida) with improved bioavailability was effective in decreasing
glucose and triglyceride levels, reducing the intensity of inflammation and liver
steatosis in obese men [62]. Another micronized formulation of RSV, SRT501, via
activation of the similar set of genes as in the case of CR, was able to counteract
negative consequences of a high-calorie diet in mice [63]. A composition
containing RSV, leucine, β-hydroxymethyl butyrate (HMB), and ketoisocaproic
acid synergistically activating sirt1 and sirt3 can induce FA oxidation and mito-
chondrial biogenesis. This combination, when tested on 3LT3-L1 preadipocytes,
was more effective in activation of sirt1 than RSV alone but also able to activate
sirt3. In c57/BL6 mice, treatment with a combination of low doses of RSV with
either HMB or leucine resulted in a reduction of body weight and improvement of
body composition accompanied by increased insulin sensitivity [64].
A variety of synthetic RSV derivatives with lower toxicity and higher potency to
activate sirt1 have been invented. The example of them is SRT1720, able to increase
deacetylation of sirt1 substrates in vitro and successfully applied in vivo to treat
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insulin resistance in animal models of type 2 diabetes [63, 65, 66]. Apart from the
favorable influence on glucose metabolism, SRT1720, by decreasing expression of
lipogenic genes, occurred to be effective in the treatment of animal models of liver
steatosis [67]. However, some studies question the beneficial effect of SRT1720 on
metabolic parameters in animals fed a high-fat diet [68]. Moreover, RSV and other
sirt1 activators (SRT1720, SRT2183, SRT1460) were found not to activate sirt1
directly but by the activation of AMPK that increases intracellular NAD+ levels and
in this way induces deacetylation of sirt1 targets [69]. However, studies on sirt1
mutations that influence the protein structure suggest that there is also a direct
interaction of RSV derivates with the sirt1 enzyme molecule [64]. In humans,
administration of SRT2104 (another RSV analogue) caused a decrease in serum
total cholesterol and triglycerides levels as well as a significant reduction of the
inflammatory response to lipopolysaccharide stimulation [70].
Despite their beneficial effects on adipose tissue metabolism, the critical issue
that may arise during the use of sirt1 activators in everyday practice is their limited
target specificity that might result in unexpected adverse effects [71]. That is why
sirt modulators are still under consideration before they can be approved for the
routine treatment of obesity and metabolic disorders.
Till now, the only aspects in which sirt inhibitors can be used to treat
obesity-associated metabolic disorders are to induce favorable changes in body
composition. sirt1-inhibiting compounds such as splitomycin, suramin,
salermide, EX-527, or sirtinol can be used to increase the amount of skeletal
muscle. This concept is based on animal studies where sirt1 KO mice display higher
muscle growth than wild-type animals and mice with muscle-specific sirt1
overexpression [64]. However, sirt1 inhibitors were not tested for that purpose
in humans.
Recently there has been a rapidly growing interest in the role of miRNAs in
fat cell development and obesity, and there is also evidence that miRNA plays a
role in the regulation of sirt activity [18, 23, 46, 72]. Therefore, one can assume that
strategies based on modifying the action of sirts by specific miRNAs may also be
useful in treating obesity. However, these studies are still at a preliminary stage.
6. Final remarks and conclusions
If the remarkable effects of sirts on adipose tissue development and metabolism
coming from animal studies hold up in humans, their activators and inhibitors may
revolutionize the treatment of obesity and associated complications. However, one
should remember that sirt activities are not limited to the regulation of metabolism
and include, also, e.g., control of longevity, oncogenesis as well as the function of
neural and cardiovascular systems. Therefore, compounds targeting sirts’ system in
order to combat excess adiposity have to be adipose tissue-specific to avoid poten-
tially harmful and counterproductive side effects of global sirt activation/inactiva-
tion. Till now such compounds have not been accepted for the clinical practice;
however, many of them are under evaluation, and it is very likely that shortly new
therapeutic strategies aimed at selective and tissue-specific modulation of sirt
activity will be registered for the treatment of obesity and its complications.
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